Chronic inflamatory bowel diseases

Yıl 2011, Cilt: 46 Sayı: 11, 70 - 78, 01.03.2011

Fügen Çullu Çokuğraş

https://doi.org/10.4274/tpa.46.39

Öz

There are two main types of chronic nbsp; inflamatory bowel diseases: crohn rsquo;s disease affecting the whole gastrointestinal system from oral cavity to nbsp; rectum and ulcerative colitis affecting only the colon A third group of such diseases consist of indeterminated nbsp; colitis Chronic inflomatory nbsp; bowel disesases emerge by means of triggering factors on a genetic basis These disease with similarities and nbsp; differences concerning clinical prognosis and laboratory findings have started nbsp; to be seen in younger popilations In this rewiew prognosis diagnosis and treatment of inflamotory bowel diseases have been discussed Turk Arch Ped nbsp; 2011; 46 Suppl: 70 8

Anahtar Kelimeler

-

Kronik enflamatuar barsak hastalıkları

Öz

Kronik enflamatuar barsak hastalıkları KİBH ağızdan rektuma kadar bütün gastrointestinal sistemi tutabilen Crohn hastalığı ve sadece kolonu tutan Ülseratif Kolit ÜK olmak üzere başlıca iki tiptir Üçüncü bir grup ta indetermine kolitlerdir Bu hastalıklar genetik bir zeminde tetik çeken etkenlerle ortaya çıkmaktadırlar Klinik seyirleri laboratuvar bulguları açısından benzerlikleri ve farklılıkları olan bu hastalıklar giderek daha küçük yaşlarda görülmektedir Bu yazıda kronik enflamatuar barsak hastalıklarının çocuk yaş grubunda seyri tanısı ve tedavisi irdelenmektedir Türk Ped Arş 2011; 46 Özel Sayı: 70 8

Anahtar Kelimeler

Barsak hastalıkları, kronik inflamatuar

Kaynakça

• Yuan Q, Winter HS. Crohn’s disease. In: Guandalini S (ed). Textbook of Pediatric Gasroenterology and Nutrition. London, Newyork: Taylor and Francis, 2004; 347-78.
• Hyams J. Crohn’s disease. In: Wyllie/Hyams (ed) s. Pediartric Gastrointestinal Disease. Second edition. Philadelphia: W.B. Saunders C, 1999: 401-18.
• Vanderhoof JA. Diarrhea. In: Wyllie/Hyams (ed) s. Pediartric Gastrointestinal Disease. Second edition. Philadelphia London Toronto: W.B. Saunders C, 1999: 32-42.
• Griffiths AM, Hugot JP. Crohn Disease. In: Walker WA, Goulet O, Kleinman RE, Sherman PM, Schneider BL, Sanderson IR (ed) s. Pediatric Gasrointestinal Disease. 6 ed. Canada: Hamilton, BC Decker, 2004; 790-824.
• Gottrand F, Colombel JF, Moreno L, et al. Incidence of inflam- matory bowel diseases in children in the Nord Pas de Calais region. Arch Fr Pediatr 1991; 48: 25-8. (Abstract)
• Roth MP, Peterson GM, McElree C, et al. Geographic origins of Jewish patients with inflammatory bowel disease. Gastroenterology 1989; 97: 900-4. (Abstract)
• Lee JCW, Lennard Jones JE. Inflammatory bowel disease in 67 families each with three or more affected first degree relatives. Gastroenterology 1996; 111: 587-96. (Abstract) / (PDF)
• Polito JM, Childs B, Mellits ED, et al. Crohn’s disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology 1996; 111: 580-6. (Abstract) / (PDF)
• Sawczenko A, Sandhu B. Presenting features of inflammatory bowel disease in children. Arch Dis Child 2003; 88: 995-1000. (Abstract)
• Satsangi J, Jewel DP, Bell JI. The genetics of inflammatory bowel disease. Gut 1997; 40: 572-4. (PDF)
• Bonen DK, Cho JH. The genetics of inflammatory bowel dis- ease. Gastroenterology 2003; 124: 521-36. (Abstract) / (PDF)
• Hampe J, Grebe J, Nikolaus S, et al. Association of NOD 2(CARD 15) genotype with clincal course of Crohn’s disease: a cohort study. Lancet 2002; 359: 1661-5. (Full Text) / (PDF)
• Bouma G, Strober W. The immunologic and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3: 521-55. Full Text)
• Stokkers PC, Reitsma PH, Tytgat GN, et al. HLA DR and DQ phenotypes in inflammatory bowel disease:a metaanalysis. Gut 1999; 45: 395-401. (Full Text) / (PDF)
• Weiss B, Shamir R, Bujanover Y, et al. NOD2/CARD 15 muta- tion analysis and genotype/phenotype correlation in Jewish pediatric patients compared with adults with Crohn’s disease. J Pediatr 2004; 145: 208-12. (Abstract) / (Full Text) / (PDF)
• Liu Y, VanKruiningen HJ, West AB, et al. Immunocytochemical evidence of Listeria, Esherichia Coli and Streptococus antigens in Crohn’s disease. Gastroenterology 1995; 108: 1396-404. (Abstract)
• Zeiter DK, Hyams JS. Recurrent abdominal pain in children. Pediatr Clin North Am. 2002; 49: 53-71. (Abstract)
• Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophsiology of inflammatory bowel disease. Clin Microbiol Rev 2002; 15: 79-94. (Abstract) / (PDF)
• Seddik M, Turck D, Gottrand F, Colombel JF. Outcome in adulthood of children and adolescents with chonic inflammatory diseases. Arch Pediatr 2001; 8: 221-3. (Abstract)
• Gramlich T, Petras RE. Pathology of inflammatory bowel disease. Sem Ped Surgery 2007; 16: 154-63. (Abstract) / (Full Text) / (PDF)
• Castellanata SP, Afzal NA, Greenberg M, et al. Diagnostic role of upper gastrointestinal endoscopy in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2004; 39: 257-61. (Abstract) / (Full Text) / (PDF)
• Palder SB, Shandling B, Bilik R, et al. Perianal complications of pediatric Crohn’s disease. J Pediatr Surg 1991; 26: 513-5. (Abstract)
• Hyams JS. Extraintestinal manifestations of inflammatory bowel disease in children. J Pediatr Gastroenterol Nutr 1994; 19: 7-12. (Abstract)
• Passo MH, Fitzgerald JF, Brandt KD. Arthritis associated with inflammatory bowel disease in children : relationship of joint dis- ease to activity and severity of bowel lesion. Dig Dis Sci 1986; 31: 492-7. (Abstract)
• Gormally SM, Bourke W, Kierse B, et al. Isolated cerebral thromboembolism and Crohn disease. Eur J Pediatr 1995; 154: 815-8. (Abstract)
• Hyams J, Markowits J, Trem W. Characterization of hepatic abormalities in children with inflammatory bowel disease. İnflamm Bowel Dis 1995; 1: 27-33. (PDF)
• Keljo DJ, Sugerman KS. Pancreatitis in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1997; 25: 108-12. (Abstract) / (Full Text)
• Bossuyt X. Serologic markers in inflammatory bowel disese. Clin Chem 2006; 52: 172-81. (Abstract) / (Full Text) / (PDF)
• Saps M, Di Lorenzo C. Diagnosis and managing functional symptoms in the child with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2004; 39: 760-2.
• Higuchi ML, Bousvaros A. Ulcerative colitis. In: Guandalini S (ed). Textbook of Pediatric Gasroenterology and Nutrition. Newyork, London: Taylor, Francis (ed) s. 2004; 385-417. (Abstract) / (Full Text) / (PDF)
• Caffari C, Darbari A. Inflammatory bowel diseas in the pediatric and adolescent patient. Gastroenterol Clin North Am 2002; 31: 275-91. (Abstract)
• Markowitz JF. Ulcerative colitis. In: Wyllie/Hyams (ed) s. Pediartric Gastrointestinal Disease. Second edition. Philadelphia, London Toronto: W.B. Saunders C, 1999: 419-432.
• Calkins BM, Lilienfeld Am, Garland CF, Mendeloff AI. Trends in incidence rates of ulcerative colitis and Crohn’s disease. Dig Dis Sci 1984; 29: 913-20. (Abstract)
• Lindberg E, Lindquist B, Holmquist L , Hildebrand H. Inflammatory bowel disease in children and adolescents in Sweden 1884-1995. J Pediatr Gastroenterol Nutr 2000; 30: 259-64. (Abstract) / (Full Text)
• Orholm M, Munkholm P, Langholz E, et al. Familial occurence of inflammatory bowel disease N Engl J Med 1991; 324: 84-88. (Abstract)
• Roussomoustakaki M, Satsangi J, Welsh K et al. Genetic mark- ers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 1997; 112: 1845-53. (Abstract) / (PDF)
• Kaser A, Zeissig S, Blumberg RS. Genes and environment: how will our concepts on the pathophysiology of IBD develop in the future? Dig Dis 2010; 28: 395-405. (PDF)
• Goodhand J, Dawson R, Hefferon M, et al. Inflammatory bowel disease in young people: the case for transitional clinics. Inflamm Bowel Dis 2010; 16: 947-52. (Abstract) / (PDF)
• Leichtner AM, Higuchi L. Ulcerative colitis. In: Walker WA, Goulet O, Kleinman RE, Sherman PM, Schneider BL, Sanderson IR (ed) s. Pediatric Gasrointestinal Disease. Fourth ed. Canada: BC Decker, 2004; 825-49.
• Hyams J, Davis P, Lerrer T, et al. Clinical outcome of ulcerative poctitis in children. J Pediatr Gastroenterol Nutr 1997; 25: 149-52. (Abstract) / (Full Text)
• Werlin SL, Grand RJ. Severe colitis in children and adolescents: diagnosis. Course and treatment. Gastroenterology 1977; 73: 828-32. (Abstract)
• Mamula P, Grzegorz W, Markowitz JE, et al. Inflammatory bowel disease in children 5 years of age and younger. Am J Gastroenterol 2002; 97: 2005-10. (Abstract)
• Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifesta- tions of inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31: 307-27. (Abstract)
• Hofley P, Roarty J, McGinnity G, et al. Asymptomatic uveitis in children with chronic inflammatory bowel diseases. J Pediatr Gastroenterol Nutr 1993; 17: 397-400. (Abstract)
• Clark JH, Fitzgerald JF, Bergstein JM. Nephrolithiasis in child- hood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1985; 4: 829-34. (Abstract)
• Sheth SG, Lamont JT. Toxic megacolon. Lancet 1998; 351: 509-13. (Full Text) / (PDF)
• Katyon ML. Cancer and pediatric inflammatory bowel disease. Sem Ped Surgery 2007; 16: 205-13. (Abstract) / (Full Text) / (PDF)
• Marchowittz J, Grancher K, Kohn N, Daum F. Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use 1990-200. Am J Gastroenterol 2002; 97: 928-32. (Full Text)
• Marchowittz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6 mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology 2000; 119: 895-902. (Abstract)
• Mamula P, Mascarenhas MR, Baldassano RN. Biological and novel therapies for inflammatory bowel disease in children. Pediatr Clin Noth Am 2002; 49:1-25. (Abstract)
• Noble A, Baldassano R, Mamula P. Novel therapeutic options in the inflammatory bowel disease world. Digestive and Liver Dis 2008; 40: 22-31. (Abstract) / (PDF)
• Markowittz J. Current treatment of inflammatory bowel disease in children. Digestive and Liver Dis 2008; 40: 16-21. (Abstract) / PDF)
• Ravikumara M, Hinsberger A, Spray CH. Role of methotrexate in the management of Crohn’s disease. J Pediatr Gastroenterol Nutr 2007; 44: 427-30. (Abstract) / (Full Text) / (PDF)
• Borelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal infflammatory lesions and restores growth in children with Crohn’s disease. Dig Liver Dis 2004; 36: 342-7. (Abstract) / (PDF)
• Martín de Carpi J, Vilar P, Prieto G, García Novo MD, Ribes C, Varea V. Infliximab in paediatric inflammatory bowel disease. J Crohn’s and Colitis 2007; 1: 2-9. (Abstract)
• Ridder L, Benninga AM, Taminiau AJM, et al. Infliximab use in children and adolescents with inflammatory bowel disease. J Ped Gastroenterol and Nutr 2007; 45: 3-14. (Abstract) / (Full Text) / (PDF)
• Borelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn’s disease. Dig Liver Dis 2004; 36: 342-7. (Abstract) / (PDF)
• Mian S, Baron H. Adalimumab a novel anti tumor necrosis factor alpha antibody in a child with refractory Crohn’s disease. J Pediatr Gastroenterol Nutr 2005; 41: 357-9. (Abstract) / (Full Text) / (PDF)
• Deslandres C, Faure C, Dirks M, et al. Open label exerience with adalimumab in pediatric Crohn’s disease patients who lost response or were intolerant to infliximab. Gastroenterology 2006; 130: 656.
• Ludvigsson JF, Krantz M, Bodin L, Stenhammar L, Lindquist B. Elementhal versus polymeric enteral nutrition in paediatric Crohn’s disease: a multicentre randomised controlled trial. Acta Paediatr 2004; 93: 327-35. (Abstract) / (PDF)
• Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrion and corticosteroids in the treatment of acute Crohn’s disease in children. J pediatr Gastroenterol Nutr 2000; 31: 8-15. (Abstract) / (Full Text)
• Akobeng AK, Richmond K, Miller V, Thomas AG. Effect of exclusive enteral nutrtional treatment on plasma antioxydant concentrations in childhood Crohn’s disease. Clinical Nutrition 2007; 26: 51-6. (Abstract) / (Full Text) / (PDF)